Q-omics provides the consensus-scored ZNF474 profile across patient tissues and cancer cell-line models. ZNF474 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF474 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, ZNF474 RNA expression shows 18,042 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, LUSC, and UVM as cancer lineages where ZNF474 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF474 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF474 survival associations across molecular data types. ZNF474 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF474 RNA expression–survival associations across cancer types. High ZNF474 expression shows unfavorable associations in BLCA, KIRC, ACC, LGG and STAD, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF474 RNA expression.
This table summarizes ZNF474 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF474. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF474 shows lower tumor expression in LUSC and LUAD and higher tumor expression in BRCA, KIRP, HNSC and CHOL. The LUSC box plot shows higher ZNF474 RNA expression in normal versus tumor tissue (log2 FC = −1.388, t-test p < 0.001).
This table shows molecular features associated with ZNF474 in patient tissues and cancer cell lines. In patient samples, ZNF474 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF474 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
